Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.

Related Articles

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.

Org Biomol Chem. 2014 Apr 28;12(16):2568-75

Authors: Cheng M, Ziora ZM, Hansford KA, Blaskovich MA, Butler MS, Cooper MA

Abstract
Dalbavancin, a semi-synthetic glycopeptide with enhanced antibiotic activity compared to vancomycin and teicoplanin, binds to the C-terminal lysyl-d-alanyl-d-alanine subunit of Lipid II, inhibiting peptidoglycan biosynthesis. In this study, micro-calorimetry and electrospray ionization (ESI)-MS have been used to investigate the relationship between oligomerisation of dalbavancin and binding of a Lipid II peptide mimic, diacetyl-Lys-d-Ala-d-Ala (Ac2-Kaa). Dalbavancin dimerised strongly in an anti-cooperative manner with ligand-binding, as was the case for ristocetin A, but not for vancomycin and teicoplanin. Dalbavancin and ristocetin A both adopt an 'closed' conformation upon ligand binding, suggesting anti-cooperative dimerisation with ligand-binding may be a general feature of dalbavancin/ristocetin A-like glycopeptides. Understanding these effects may provide insight into design of novel dalbavancin derivatives with cooperative ligand-binding and dimerisation characteristics that could enhance antibiotic activity.

PMID: 24608916 [PubMed - indexed for MEDLINE]